Staphylococcus Lugdunensis Endocarditis

Etienne, J.; Pangon, B.; Leport, Catherine; Wolff, Marcelo; Clair, Bernard; Perronne, C.; Brun, Y.; Bure, A

doi:10.1016/s0140-6736(89)91770-4

Cited by 64 publications

(24 citation statements)

References 4 publications

(1 reference statement)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This organism is uniformly susceptible in vitro to most antibiotics. [83][84][85][86][87][88][89] Most experts recommend that endocarditis caused by this organism be treated with standard regimens based on the in vitro susceptibility profiles of the strain. The patient also should be monitored carefully for the development of periannular extension or extracardiac spread of infection.…”

Section: Coagulase-negative Staphylococcimentioning

confidence: 99%

See 1 more Smart Citation

Infective Endocarditis

Baddour¹,

Wilson²,

Bayer³

et al. 2005

Circulation

1,274

436

View full text Add to dashboard Cite

Background-Despite advances in medical, surgical, and critical care interventions, infective endocarditis remains a disease that is associated with considerable morbidity and mortality. The continuing evolution of antimicrobial resistance among common pathogens that cause infective endocarditis creates additional therapeutic issues for physicians to manage in this potentially life-threatening illness. Methods and Results-This work represents the third iteration of an infective endocarditis "treatment" document developed by the American Heart Association under the auspices of the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease of the Young. It updates recommendations for diagnosis, treatment, and management of complications of infective endocarditis. A multidisciplinary committee of experts drafted this document to assist physicians in the evolving care of patients with infective endocarditis in the new millennium. This extensive document is accompanied by an executive summary that covers the key points of the diagnosis, antimicrobial therapy, and management of infective endocarditis. For the first time, an evidence-based scoring system that is used by the American College of Cardiology and the American Heart Association was applied to treatment recommendations. Tables also have been included that provide input on the use of echocardiography during diagnosis and treatment of infective endocarditis, evaluation and treatment of culture-negative endocarditis, and short-term and long-term management of patients during and after completion of antimicrobial treatment. To assist physicians who care for children, pediatric dosing was added to each treatment regimen. Conclusions-The recommendations outlined in this update should assist physicians in all aspects of patient care in the diagnosis, medical and surgical treatment, and follow-up of infective endocarditis, as well as management of associated complications. Clinical variability and complexity in infective endocarditis, however, dictate that these guidelines be used to support and not supplant physician-directed decisions in individual patient management. (Circulation. 2005; 111:e394-e433.)

show abstract

Section: Coagulase-negative Staphylococcimentioning

confidence: 99%

“…The patient also should be monitored carefully for the development of periannular extension or extracardiac spread of infection. The microbiological differentiation of S lugdunensis from other CoNS may be difficult, 89 and many laboratories do not have the capability to assign species identification to CoNS isolates.…”

Section: Coagulase-negative Staphylococcimentioning

confidence: 99%

Infective Endocarditis

Baddour¹,

Wilson²,

Bayer³

et al. 2005

Circulation

1,274

436

View full text Add to dashboard Cite

show abstract

“…12 The clinical relevance of S. lugdunensis was first described when it was implicated as a causative organism in endocarditis. 13 Since this time more than 80 further case reports of S. lugdunensis endocarditis have been reported, primarily involving native left-sided valves. 11 A review of S. lugdunensis endocarditis estimated its mortality to be 50%, with mortality rates higher with S. lugdunensis than other CoNS.…”

Section: Discussionmentioning

confidence: 99%

Staphylococcus lugdunensis: case report and discussion

Donoghue

Vekic

Wehrhahn

et al. 2014

Australasian Journal of Dermatology

View full text Add to dashboard Cite

“…In 1989, Etienne et al described two cases of native valve endocarditis and one case of prosthetic valve endocarditis in which S. lugdunensis was retrospectively identified as being the causative agent (53). In each case, the infection was aggressive, involving valve destruction and abscess formation, and ultimately resulted in the deaths of two of the three patients.…”

Section: Clinical Diseasementioning

confidence: 99%

From Clinical Microbiology to Infection Pathogenesis: How Daring To Be Different Works forStaphylococcus lugdunensis

2008

View full text Add to dashboard Cite

SUMMARY Staphylococcus lugdunensis has gained recognition as an atypically virulent pathogen with a unique microbiological and clinical profile. S. lugdunensis is coagulase negative due to the lack of production of secreted coagulase, but a membrane-bound form of the enzyme present in some isolates can result in misidentification of the organism as Staphylococcus aureus in the clinical microbiology laboratory. S. lugdunensis is a skin commensal and an infrequent pathogen compared to S. aureus and S. epidermidis, but clinically, infections caused by this organism resemble those caused by S. aureus rather than those caused by other coagulase-negative staphylococci. S. lugdunensis can cause acute and highly destructive cases of native valve endocarditis that often require surgical treatment in addition to antimicrobial therapy. Other types of S. lugdunensis infections include abscess and wound infection, urinary tract infection, and infection of intravascular catheters and other implanted medical devices. S. lugdunensis is generally susceptible to antimicrobial agents and shares CLSI antimicrobial susceptibility breakpoints with S. aureus. Virulence factors contributing to this organism's heightened pathogenicity remain largely unknown. Those characterized to date suggest that the organism has the ability to bind to and interact with host cells and to form biofilms on host tissues or prosthetic surfaces.

show abstract

Staphylococcus Lugdunensis Endocarditis

Cited by 64 publications

References 4 publications

Infective Endocarditis

Infective Endocarditis

Staphylococcus lugdunensis: case report and discussion

From Clinical Microbiology to Infection Pathogenesis: How Daring To Be Different Works forStaphylococcus lugdunensis

Contact Info

Product

Resources

About